Search

Your search keyword '"Abrisqueta, Pau"' showing total 20 results

Search Constraints

Start Over You searched for: Author "Abrisqueta, Pau" Remove constraint Author: "Abrisqueta, Pau" Journal clinical lymphoma, myeloma and leukemia Remove constraint Journal: clinical lymphoma, myeloma and leukemia
20 results on '"Abrisqueta, Pau"'

Search Results

1. Real-World Characteristics and Outcome of Patients Treated With Single-Agent Ibrutinib for Chronic Lymphocytic Leukemia in Spain (IBRORS-LLC Study)

3. ABCL-073 Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (Pola-R-CHP) Versus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP) Therapy in Patients With Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Results From the Phase III POLARIX Study

5. ABCL-417 First Data From Subcutaneous Epcoritamab + Polatuzumab Vedotin Rituximab, Cyclophosphamide Doxorubicin, and Prednisone (Pola-RCHP) for First-Line Diffuse Large B-Cell Lymphoma (DLBCL): EPCORE NHL-5

7. CLL-573 Characterization and Outcomes of the Spanish Patients Included in the GLOW and CAPTIVATE-FD Studies: Ibrutinib Plus Venetoclax for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL)

9. First Data From Subcutaneous Epcoritamab + Polatuzumab Vedotin, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (Pola-R-CHP) for First-Line Diffuse Large B-Cell Lymphoma (DLBCL): EPCORE NHL-5

11. Characterization and Outcomes of the Spanish Patients Included in the GLOW and CAPTIVATE-FD Studies: Ibrutinib Plus Venetoclax for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL)

12. IBCL-474 Epcoritamab + R2 Regimen and Responses in Patients With High-Risk Follicular Lymphoma, Regardless of POD24 Status

14. ABCL-450 Five-Year Efficacy and Safety of Tafasitamab in Patients With Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): Final Results From the Phase II L-MIND Study

15. POSTER: IBCL-474 Epcoritamab + R2 Regimen and Responses in Patients With High-Risk Follicular Lymphoma, Regardless of POD24 Status

16. POSTER: ABCL-450 Five-Year Efficacy and Safety of Tafasitamab in Patients With Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): Final Results From the Phase II L-MIND Study

19. Poster: ABCL-073 Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (Pola-R-CHP) Versus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP) Therapy in Patients With Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Results From the Phase III POLARIX Study

20. Oral Abstract: ABCL-073 Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (Pola-R-CHP) Versus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP) Therapy in Patients With Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Results From the Phase III POLARIX Study

Catalog

Books, media, physical & digital resources